Comment: it wouldn’t surprise me AT ALL that if a 4x concentration provided longer duration without higher AE (eg Ptosis). Note that I expect this kind of dilution/injection-pattern change and its impact on (separately) efficacy and AE to vary immensely for different treatment locales (glabellar vs frontalis vs cervical dystonia vs spastic limb). And I virtually guarantee EOLS mgt is much more capable of dealing flexibly with this difficult location-specific-difference. (Foley seems incapable of flexibility.)
Agree. Partly. It’s *currently*, without a price cut, a marketing ploy. But wager: 18 months from now EOLS will still be growing at least as fast as RVNC (within 15% of Q/Q percentage) for US neuronmodulators.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.